BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,350,000 shares, a decline of 29.7% from the October 31st total of 1,920,000 shares. Currently, 19.6% of the shares of the stock are sold short. Based on an average trading volume of 5,610,000 shares, the days-to-cover ratio is presently 0.2 days.

BioVie Trading Up 3.3 %

Shares of NASDAQ:BIVI traded up $0.09 on Friday, hitting $2.80. The company had a trading volume of 1,095,244 shares, compared to its average volume of 1,691,573. The company has a market cap of $49.76 million, a PE ratio of -0.24 and a beta of 0.40. BioVie has a 52-week low of $1.04 and a 52-week high of $33.10. The business has a 50 day moving average of $2.27 and a 200 day moving average of $1.64.

BioVie (NASDAQ:BIVI) last announced its earnings results on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.